STAT: One-quarter of the world may not get a Covid-19 vaccine until 2022, experts warn
“As wealthy governments race to lock in supplies of Covid-19 vaccines, nearly a quarter of the world’s population — mostly in low- and middle-income countries — will not have access to a shot until 2022, according to a new analysis. … Looked at another way, the projected vaccine courses per capita by country show Canada, followed by Australia, the U.K., Japan, the European Union, and U.S., have reserved at least one vaccine course per person. Canada has reserved 9.5 doses, or well over four courses, per person. By contrast, low- to middle-income countries, such as Brazil and Indonesia, reserved less than one course for every two people…” (Silverman, 12/15).

U.N. News: Vaccines for all, an ‘acid test’ in COVID-19 battle
“Equitable distribution of COVID-19 vaccines will represent an ‘acid test’ for the international community, the president of the U.N. Economic and Social Council (ECOSOC) told journalists on Wednesday, highlighting the importance of global cooperation and solidarity in beating back the disease…” (12/16).

Wall Street Journal: Covid-19 Vaccines: What’s Coming and When?
“Some 200 Covid-19 vaccines are in development around the world, according to the World Health Organization, each one promising to protect people from the deadly coronavirus and allow them to go back to work and school…” (Rivas et al., 12/14).

AP: WHO: Vaccination in Asia-Pacific expected mid or late 2021 (Milko, 12/17).

AP: Russia’s COVID-19 vaccine rollout draws wary, mixed response (Litvinova, 12/17).

Reuters: Chilean health regulator approves Pfizer-BioNTech vaccine for emergency use (Cambero et al., 12/16).

Reuters: Indonesia pledges free COVID-19 vaccines, with president first in line (Jefriando, 12/16).

Reuters: Nigeria expects to get its first COVID-19 vaccine doses in January (Onuah/George, 12/16).

USA TODAY: FDA advisory committee to consider second COVID-19 vaccine, this one from Moderna, during all-day meeting (Weintraub, 12/17).

Washington Post: An FDA committee is reviewing Moderna’s coronavirus vaccine. Here’s what to look for (McGinley/Johnson, 12/17).